RxDoctor Payments Data

David Cohen, MD

Urology · Seaford, DENPI 1922191568

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,408 of the $3,808 with a category attached, or 63.3%. Procept Biorobotics Corporation accounts for 65.4% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $1,441, 2.2 times the $658 reported in 2019.

$3,808in general payments, 2019–2025

Across 62 payments — averaging $61.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$2K
  • Boston Scientific$390
  • Astellas Pharma US Inc$184
  • Sumitomo Pharma America, Inc.$167
  • Myriad Women's Health, Inc.$89
  • Ferring Pharmaceuticals Inc.$76
  • plus $412 from 12 others

What the payments were for

  • Travel & lodging$2,40863%
  • Food & beverage$1,39937%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,808 in reported general payments places this provider in the 65th percentile of 33 urology providers in Delaware.

See all urology providers in Delaware

Medicare billing

Part B allowed, 2024
$117,362
Medicare patients
459
Services billed
1,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron67$61,836
GemtesaVibegron13$11,520
Tamsulosin Hcl508$5,961
Finasteride312$4,888
Fesoterodine Fumarate ErFesoterodine Fumarate17$3,167
Oxybutynin Chloride ErOxybutynin Chloride126$2,792
Silodosin29$2,586
Alfuzosin Hcl ErAlfuzosin Hcl82$2,475
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst26$1,183
Ciprofloxacin Hcl80$345
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip19$309
Sildenafil Citrate19$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$184$61,83667 claims
Sumitomo Pharma America, Inc.Gemtesa$167$11,52013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 33 urology providers in Delaware.

Other urology in Seaford

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →